AstraZeneca plc (AZN) Raised to “Outperform” at Credit Suisse Group
Credit Suisse Group upgraded shares of AstraZeneca plc (LON:AZN) from a neutral rating to an outperform rating in a research note issued to investors on Monday, Marketbeat.com reports. Credit Suisse Group currently has GBX 5,800 ($77.07) price target on the biopharmaceutical company’s stock, up from their previous price target of GBX 4,800 ($63.78).
Several other equities research analysts also recently commented on the stock. Citigroup Inc. reaffirmed a buy rating and set a GBX 6,000 ($79.72) price objective on shares of AstraZeneca plc in a report on Thursday, July 13th. Barclays PLC set a GBX 6,300 ($83.71) price objective on shares of AstraZeneca plc and gave the company a buy rating in a report on Wednesday, September 13th. Liberum Capital reaffirmed a buy rating and set a GBX 4,800 ($63.78) price objective on shares of AstraZeneca plc in a report on Tuesday, September 5th. Deutsche Bank AG reaffirmed a buy rating and set a GBX 5,700 ($75.74) price objective on shares of AstraZeneca plc in a report on Friday, June 30th. Finally, Natixis raised shares of AstraZeneca plc from a neutral rating to a buy rating and upped their price objective for the company from GBX 5,000 ($66.44) to GBX 5,738 ($76.24) in a report on Wednesday, September 6th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of GBX 5,172.64 ($68.73).
Shares of AstraZeneca plc (LON AZN) opened at 5190.00 on Monday. The stock’s 50 day moving average is GBX 4,904.35 and its 200-day moving average is GBX 4,912.64. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00. The firm’s market cap is GBX 65.71 billion.
In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of AstraZeneca plc stock in a transaction on Thursday, July 27th. The shares were acquired at an average cost of GBX 4,370 ($58.07) per share, for a total transaction of £1,704.30 ($2,264.55).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.